Mallinckrodt (MNK) Tops Q1 EPS by 22c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UPDATE: Mallinckrodt plc (MNK) PT Lowered to $18 at Goldman Sachs
May 10, 2018 8:02 AM EDT(Updated - May 10, 2018 8:03 AM EDT)
(updated to correct price target)
Goldman Sachs lowered its price target on Mallinckrodt plc (NYSE: MNK) to $18.00 (from $21.00) while maintaining a Neutral rating.
... MoreCantor Fitzgerald Remains Bullish on Mallinckrodt (MNK) Following 1Q
May 9, 2018 7:56 AM EDTCantor Fitzgerald reiterated an Overweight rating and $42.00 price target on Mallinckrodt plc (NYSE: MNK) following the company's 1Q earnings report. MNK reported EPS of $1.31, $0.23 above FactSet consensus. MNK did not change its 2018 EPS guidance of $6.00-6.50 (FactSet consensus was $6.17).
Analyst Louise Chen believes that... More
Mallinckrodt plc (MNK) PT Lowered to $29 at BMO Capital
May 9, 2018 7:47 AM EDTBMO Capital lowered its price target on Mallinckrodt plc (NYSE: MNK) to $29.00 (from $33.00) while maintaining a Outperform rating.
Analyst Gary Nachman commented, "MNK delivered good results in 1Q, particularly relative to lowered expectations for Acthar. Management indicated it is making headway stabilizing that... More
Mallinckrodt (MNK) Provides Facts on H.P. Acthar Gel in Resonse to CBS' 60 Minutes
May 7, 2018 7:01 AM EDTMallinckrodt Pharmaceuticals (NYSE: MNK), in response to a segment aired on CBS' 60 Minutes on Sunday, May 6, has posted facts related to H.P. Acthar® Gel (repository corticotropin injection) on its website at www.mallinckrodt.com/acthar.
... MoreMallinckrodt (MNK) Seen as Target of Negative Upcoming 60 Minutes Episode
May 4, 2018 10:06 AM EDTMallinckrodt (NYSE: MNK) is seen as the target of an upcoming 60 Minutes episode.
"THE ROCKFORD FILE A look at the fight that Rockford, Ill., took up against the high cost of prescription drugs explains why they cost more in the U.S.... More
Mallinckrodt (MNK) Reports Negative FDA Advisory Committee Vote on Stannsoporfin for Treatment of Newborns at Risk of Developing Severe Jaundice
May 4, 2018 6:21 AM EDTMallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today expressed disappointment that, in a joint meeting, the U.S. Food and Drug Administration's (FDA's) Gastrointestinal Drugs Advisory Committee... More
